Related Experiment Videos

New drugs for prostate cancer?

J Waxman, R Roylance

European Journal of Cancer (Oxford, England : 1990)

|August 26, 1998

Summary

No abstract available in PubMed .

Related Concept Videos

Articles linked to this work by shared authors, journal, and citation graph.

Disruption of androgen receptor-cofactor interactions by the RNA-binding protein FUS/TLS alters androgen signalling in prostate cancer.

Oncogene·2026

Final analysis of the ALTTO trial: adjuvant trastuzumab in sequence or in combination with lapatinib in patients with HER2-positive early breast cancer [BIG 2-06/NCCTG N063D (Alliance)].

ESMO open·2024

Expert UK consensus on the definition of high risk of recurrence in HER2-negative early breast cancer: A modified Delphi panel.

Breast (Edinburgh, Scotland)·2023

A Multicentre Retrospective Study of Fulvestrant Use and Efficacy in Advanced/Metastatic Breast Cancer.

Clinical oncology (Royal College of Radiologists (Great Britain))·2022

A survey to determine usual care after cancer treatment within the United Kingdom national health service.

BMC cancer·2017

Pictilisib PI3Kinase inhibitor (a phosphatidylinositol 3-kinase [PI3K] inhibitor) plus paclitaxel for the treatment of hormone receptor-positive, HER2-negative, locally recurrent, or metastatic breast cancer: interim analysis of the multicentre, placebo-controlled, phase II randomised PEGGY study.

Annals of oncology : official journal of the European Society for Medical Oncology·2016

See all related articles